Blocking PD-L1+ NK cells with anti-PD-L1 improves degranulation and cytokine production, as well as control tumor in vivo, indicating that NK cells may contribute to the success of checkpoint inhibition independent of PD-1 expression (364). The gene discussed is CD274; the disease is neoplasm.